JP2024520427A5 - - Google Patents
Info
- Publication number
- JP2024520427A5 JP2024520427A5 JP2023572797A JP2023572797A JP2024520427A5 JP 2024520427 A5 JP2024520427 A5 JP 2024520427A5 JP 2023572797 A JP2023572797 A JP 2023572797A JP 2023572797 A JP2023572797 A JP 2023572797A JP 2024520427 A5 JP2024520427 A5 JP 2024520427A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- sequence shown
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163192783P | 2021-05-25 | 2021-05-25 | |
| US63/192,783 | 2021-05-25 | ||
| PCT/US2022/030814 WO2022251283A1 (en) | 2021-05-25 | 2022-05-25 | T cell receptors targeting ras mutations and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520427A JP2024520427A (ja) | 2024-05-24 |
| JP2024520427A5 true JP2024520427A5 (https=) | 2025-06-03 |
Family
ID=84230235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023572797A Pending JP2024520427A (ja) | 2021-05-25 | 2022-05-25 | Ｒａｓ変異を標的とするｔ細胞受容体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240091361A1 (https=) |
| EP (1) | EP4347639A4 (https=) |
| JP (1) | JP2024520427A (https=) |
| KR (1) | KR20240013750A (https=) |
| CN (1) | CN117545766A (https=) |
| AU (1) | AU2022283277A1 (https=) |
| BR (1) | BR112023024595A2 (https=) |
| CA (1) | CA3219923A1 (https=) |
| IL (1) | IL308755A (https=) |
| MX (1) | MX2023014073A (https=) |
| WO (1) | WO2022251283A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024039576A2 (en) * | 2022-08-19 | 2024-02-22 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting ras mutations and uses thereof |
| AU2024228388A1 (en) * | 2023-02-27 | 2025-10-02 | Adaptive Biotechnologies Corp. | Therapeutic t cell receptors targeting kras g12d |
| CN118812698A (zh) * | 2023-04-19 | 2024-10-22 | 香雪生命科学技术（广东）有限公司 | 一种识别kras突变的高亲和力t细胞受体及其应用 |
| AU2024269870A1 (en) * | 2023-05-05 | 2025-11-20 | Board Of Regents, The University Of Texas System | Multi-receptor natural killer cells |
| AU2024339041A1 (en) * | 2023-09-05 | 2026-04-16 | Bluesphere Bio, Inc. | T cell receptors targeting an npm1 neoantigen |
| WO2025137468A1 (en) * | 2023-12-22 | 2025-06-26 | Abata Therapeutics, Inc. | Cell therapies for type 1 diabetes |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20171164T1 (hr) * | 2010-09-20 | 2017-10-20 | Biontech Cell & Gene Therapies Gmbh | Antigen-specifični t stanični receptori i t stanični epitopi |
| US20210147550A1 (en) * | 2017-08-18 | 2021-05-20 | Joshua Michael Francis | Antigen-binding proteins targeting shared antigens |
| CR20200287A (es) * | 2017-12-04 | 2020-11-11 | Us Health | Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado |
| CA3116749A1 (en) * | 2018-10-24 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla-a3-restricted t cell receptors against mutated ras |
| WO2020154617A1 (en) * | 2019-01-25 | 2020-07-30 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting mutant ras |
| CN114026116A (zh) * | 2019-02-20 | 2022-02-08 | 弗雷德哈钦森癌症研究中心 | Ras新抗原特异性结合蛋白及其用途 |
-
2022
- 2022-05-25 CN CN202280045185.0A patent/CN117545766A/zh active Pending
- 2022-05-25 AU AU2022283277A patent/AU2022283277A1/en active Pending
- 2022-05-25 EP EP22812027.5A patent/EP4347639A4/en active Pending
- 2022-05-25 BR BR112023024595A patent/BR112023024595A2/pt not_active Application Discontinuation
- 2022-05-25 CA CA3219923A patent/CA3219923A1/en active Pending
- 2022-05-25 IL IL308755A patent/IL308755A/en unknown
- 2022-05-25 JP JP2023572797A patent/JP2024520427A/ja active Pending
- 2022-05-25 WO PCT/US2022/030814 patent/WO2022251283A1/en not_active Ceased
- 2022-05-25 KR KR1020237041629A patent/KR20240013750A/ko active Pending
- 2022-05-25 MX MX2023014073A patent/MX2023014073A/es unknown
-
2023
- 2023-11-22 US US18/517,835 patent/US20240091361A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024520427A5 (https=) | ||
| JP7781243B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP2022527635A5 (https=) | ||
| JP7803939B2 (ja) | Ｋｒａｓ変異に特異的ｔ細胞受容体のスクリーニング及び抗腫瘍用途 | |
| JP7346294B2 (ja) | 対合が改善されたｔ細胞受容体ｔ細胞 | |
| ES2968802T3 (es) | Células T transfectadas y receptores de células T para su uso en inmunoterapia contra el cáncer | |
| JP2021533777A5 (https=) | ||
| JP2021520198A5 (https=) | ||
| JP2022050400A5 (https=) | ||
| CN108884136A (zh) | 用于癌症免疫治疗的转染t细胞和t细胞受体 | |
| JP2017523784A5 (https=) | ||
| JP2017536825A (ja) | 抗突然変異ｋｒａｓ ｔ細胞受容体 | |
| JP2022528030A5 (https=) | ||
| JP2022527267A5 (https=) | ||
| JP2021512637A5 (https=) | ||
| JP2025063321A5 (https=) | ||
| JP2018506287A5 (https=) | ||
| JP2023538116A5 (https=) | ||
| US12421290B2 (en) | CD22-specific T cell receptors and adoptive T cell therapy for treatment of B cell malignancies | |
| JP2022537553A5 (https=) | ||
| TW202330589A (zh) | 治療 | |
| JP2022548112A5 (https=) | ||
| Turner et al. | TCR α-chain usage can determine antigen-selected TCR β-chain repertoire diversity | |
| JP2022502078A5 (https=) | ||
| JP2023526416A5 (https=) |